Literature DB >> 35040974

Error in Article Information.

.   

Abstract

Entities:  

Year:  2022        PMID: 35040974      PMCID: PMC8767434          DOI: 10.1001/jamanetworkopen.2021.46944

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


× No keyword cloud information.
In the Original Investigation titled “Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial,”[1] published on November 29, 2021, the authors omitted the following disclosures: Dr Menichetti reported serving as the principal investigator for an AstraZeneca–sponsored trial and a Toscana Life Science-sponsored trial evaluating monoclonal antibodies for SARS-CoV-2 (for which no personal fees were received), and receiving speaker honoraria or advisory board or support for meetings from Angelini, Menarini, Correvio, MSD, Pfizer, Astellas, Gilead, BMS, Janssen, ViiV, BioMerieux, Biotest, Becton-Dickinson, Pfizer, Shionogi, Roche, GSK, Advanz Pharma, and ThermoFisher in the last 3 years (outside the submitted work); Dr Bartoloni reported receiving study grants from MSD, ViiV Healthcare, and Nordic Pharma and receiving fees for presentations at local congresses or expert meeting from Pfizer and MSD in the last 3 years (outside the submitted work); Dr Marchetti reported receiving grants for lectures, advisory board, or conferences by Gilead, ViiV, and Janssen in the last 3 years (outside the submitted work); Dr d’Arminio Monforte reported receiving grants for lectures, advisory board, or conferences by Gilead, ViiV, MSD, Angelini, and Janssen in the last 3 years (outside the submitted work); Dr Saracino reported receiving grants for research and/or educational purposes from Gilead, ViiV, MSD, Abbvie, Janssen, Shionogi, and Pfizer in the last 3 years (outside the submitted work); Dr Castagna reported receiving personal fees from ViiV, MSD, Gilead, Janssen, and Theratecnologies in the last 3 years (outside the submitted work); and Dr Falcone reported receiving grants and speaker honoraria from Angelini, Shionogi, MSD, Pfizer, Gilead, Menarini, and Nordic Pharma in the last 3 years (outside the submitted work). The corresponding author has explained this omission in a Comment[2] and the article has been corrected.[1] This article was previously corrected on December 21, 2021, to correct errors in the Results section, Figure 1, Table 1, and Article Information.[3]
  2 in total

1.  Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.

Authors:  Francesco Menichetti; Patrizia Popoli; Maria Puopolo; Stefania Spila Alegiani; Giusy Tiseo; Alessandro Bartoloni; Giuseppe Vittorio De Socio; Sauro Luchi; Pierluigi Blanc; Massimo Puoti; Elena Toschi; Marco Massari; Lucia Palmisano; Giuseppe Marano; Margherita Chiamenti; Laura Martinelli; Silvia Franchi; Carlo Pallotto; Lorenzo Roberto Suardi; Barbara Luciani Pasqua; Marco Merli; Plinio Fabiani; Luca Bertolucci; Beatrice Borchi; Sara Modica; Sara Moneta; Giulia Marchetti; Antonella d'Arminio Monforte; Laura Stoppini; Nadia Ferracchiato; Stefania Piconi; Claudio Fabbri; Enrico Beccastrini; Riccardo Saccardi; Andrea Giacometti; Sara Esperti; Piera Pierotti; Laura Bernini; Claudia Bianco; Sara Benedetti; Alessandra Lanzi; Paolo Bonfanti; Marco Massari; Spartaco Sani; Annalisa Saracino; Antonella Castagna; Luigia Trabace; Maria Lanza; Daniele Focosi; Alessandro Mazzoni; Mauro Pistello; Marco Falcone
Journal:  JAMA Netw Open       Date:  2021-11-01

2.  Errors in Results, Figure 1, Table 1, and Article Information.

Authors: 
Journal:  JAMA Netw Open       Date:  2021-12-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.